246 related articles for article (PubMed ID: 26359802)
1. CXCL13 and CCL11 Serum Levels and Lymphoma and Disease Activity in Primary Sjögren's Syndrome.
Nocturne G; Seror R; Fogel O; Belkhir R; Boudaoud S; Saraux A; Larroche C; Le Guern V; Gottenberg JE; Mariette X
Arthritis Rheumatol; 2015 Dec; 67(12):3226-33. PubMed ID: 26359802
[TBL] [Abstract][Full Text] [Related]
2. Serum, but Not Saliva, CXCL13 Levels Associate With Infiltrating CXCL13+ Cells in the Minor Salivary Gland Lesions and Other Histologic Parameters in Patients With Sjögren's Syndrome.
Chatzis L; Goules AV; Stergiou IE; Voulgarelis M; Tzioufas AG; Kapsogeorgou EK
Front Immunol; 2021; 12():705079. PubMed ID: 34484201
[TBL] [Abstract][Full Text] [Related]
3. Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sjögren's syndrome.
Traianos EY; Locke J; Lendrem D; Bowman S; Hargreaves B; Macrae V; ; Tarn JR; Ng WF
Rheumatol Int; 2020 Apr; 40(4):541-548. PubMed ID: 32047959
[TBL] [Abstract][Full Text] [Related]
4. Chemokine saliva levels in patients with primary Sjögren's syndrome, associated Sjögren's syndrome, pre-clinical Sjögren's syndrome and systemic autoimmune diseases.
Hernández-Molina G; Michel-Peregrina M; Hernández-Ramírez DF; Sánchez-Guerrero J; Llorente L
Rheumatology (Oxford); 2011 Jul; 50(7):1288-92. PubMed ID: 21330342
[TBL] [Abstract][Full Text] [Related]
5. Secondary tumours in Sjögren's syndrome.
Kovács L; Szodoray P; Kiss E
Autoimmun Rev; 2010 Feb; 9(4):203-6. PubMed ID: 19602455
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic role of CXCL13 biomarker in primary Sjogren's syndrome patients with parotid non-Hodgkin's lymphoma complication.
Badarinza M; Serban O; Maghear L; Pelea MA; Rosca RI; Fodor D; Stancu B
Med Clin (Barc); 2023 Jun; 160(11):484-488. PubMed ID: 37005121
[TBL] [Abstract][Full Text] [Related]
7. Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome.
Nocturne G; Virone A; Ng WF; Le Guern V; Hachulla E; Cornec D; Daien C; Vittecoq O; Bienvenu B; Marcelli C; Wendling D; Amoura Z; Dhote R; Lavigne C; Fior R; Gottenberg JE; Seror R; Mariette X
Arthritis Rheumatol; 2016 Apr; 68(4):977-85. PubMed ID: 26606524
[TBL] [Abstract][Full Text] [Related]
8. Molecular B-cell clonality assay in minor salivary glands as a useful tool for the lymphoma risk assessment in Sjögren's syndrome.
Benyamine A; Poulet A; Belenotti P; Nihous H; Ene N; Jarrot PA; Swiader L; Mancini J; Beaufils N; Essaydi A; Gabert J; Weiller PJ; Kaplanski G
Joint Bone Spine; 2024 May; 91(3):105686. PubMed ID: 38161050
[TBL] [Abstract][Full Text] [Related]
9. Distinct profiles of Sjögren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF.
Szodoray P; Alex P; Jonsson MV; Knowlton N; Dozmorov I; Nakken B; Delaleu N; Jonsson R; Centola M
Clin Immunol; 2005 Nov; 117(2):168-76. PubMed ID: 16126006
[TBL] [Abstract][Full Text] [Related]
10. Predictive significance of CCL21 and CXCL13 levels in the minor salivary glands of patients with Sjögren's syndrome.
Lee KE; Kang JH; Yim YR; Kim JE; Lee JW; Wen L; Park DJ; Kim TJ; Park YW; Yoon KC; Lee JS; Lee SS
Clin Exp Rheumatol; 2017; 35(2):234-240. PubMed ID: 27782867
[TBL] [Abstract][Full Text] [Related]
11. Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjögren's syndrome.
Amft N; Curnow SJ; Scheel-Toellner D; Devadas A; Oates J; Crocker J; Hamburger J; Ainsworth J; Mathews J; Salmon M; Bowman SJ; Buckley CD
Arthritis Rheum; 2001 Nov; 44(11):2633-41. PubMed ID: 11710719
[TBL] [Abstract][Full Text] [Related]
12. Early BAFF receptor blockade mitigates murine Sjögren's syndrome: Concomitant targeting of CXCL13 and the BAFF receptor prevents salivary hypofunction.
Sharma A; Kiripolsky J; Klimatcheva E; Howell A; Fereidouni F; Levenson R; Rothstein TL; Kramer JM
Clin Immunol; 2016 Mar; 164():85-94. PubMed ID: 26826598
[TBL] [Abstract][Full Text] [Related]
13. BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands.
Quartuccio L; Salvin S; Fabris M; Maset M; Pontarini E; Isola M; De Vita S
Rheumatology (Oxford); 2013 Feb; 52(2):276-81. PubMed ID: 22879463
[TBL] [Abstract][Full Text] [Related]
14. Brief Report: Monoclonal Gammopathy and Risk of Lymphoma and Multiple Myeloma in Patients With Primary Sjögren's Syndrome.
Tomi AL; Belkhir R; Nocturne G; Desmoulins F; Berge E; Pavy S; Miceli-Richard C; Mariette X; Seror R
Arthritis Rheumatol; 2016 May; 68(5):1245-50. PubMed ID: 26636425
[TBL] [Abstract][Full Text] [Related]
15. Diminished CXCR5 expression in peripheral blood of patients with Sjögren's syndrome may relate to both genotype and salivary gland homing.
Aqrawi LA; Ivanchenko M; Björk A; Ramírez Sepúlveda JI; Imgenberg-Kreuz J; Kvarnström M; Haselmayer P; Jensen JL; Nordmark G; Chemin K; Skarstein K; Wahren-Herlenius M
Clin Exp Immunol; 2018 Jun; 192(3):259-270. PubMed ID: 29453859
[TBL] [Abstract][Full Text] [Related]
16. CXCL13 as biomarker for histological involvement in Sjögren's syndrome.
Colafrancesco S; Priori R; Smith CG; Minniti A; Iannizzotto V; Pipi E; Lucchesi D; Pontarini E; Nayar S; Campos J; Arienzo F; Fusconi M; Cerbelli B; Giordano C; Valesini G; Bombardieri M; Fisher BA; Barone F
Rheumatology (Oxford); 2020 Jan; 59(1):165-170. PubMed ID: 31274159
[TBL] [Abstract][Full Text] [Related]
17. B-Cell Activation Biomarkers in Salivary Glands Are Related to Lymphomagenesis in Primary Sjögren's Disease: A Pilot Monocentric Exploratory Study.
Bruno D; Tolusso B; Lugli G; Di Mario C; Petricca L; Perniola S; Bui L; Benvenuto R; Ferraccioli G; Alivernini S; Gremese E
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542233
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological factors relating malignant lymphoma with Sjögren's syndrome.
Anaya JM; McGuff HS; Banks PM; Talal N
Semin Arthritis Rheum; 1996 Apr; 25(5):337-46. PubMed ID: 8778989
[TBL] [Abstract][Full Text] [Related]
19. Sjögren's syndrome in patients with newly diagnosed untreated non-Hodgkin's lymphoma.
Andonopoulos AP; Tiniakou M; Melachrinou M; Sfountouris H; Bounas A; Zervas C; Zoumbos NC
Rev Rhum Engl Ed; 1997 May; 64(5):287-92. PubMed ID: 9190001
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers of lymphoma in Sjögren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study.
Quartuccio L; Isola M; Baldini C; Priori R; Bartoloni Bocci E; Carubbi F; Maset M; Gregoraci G; Della Mea V; Salvin S; De Marchi G; Luciano N; Colafrancesco S; Alunno A; Giacomelli R; Gerli R; Valesini G; Bombardieri S; De Vita S
J Autoimmun; 2014 Jun; 51():75-80. PubMed ID: 24231556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
